v2.4.0.8
Joint Ventures and Other Equity Method Affiliates - Textual (Detail) (USD $)
12 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
AstraZeneca LP [Member]
Dec. 31, 2012
AstraZeneca LP [Member]
Dec. 31, 2011
AstraZeneca LP [Member]
Dec. 31, 1998
AstraZeneca LP [Member]
Dec. 31, 1993
AMI [Member]
Dec. 31, 2013
Sanofi Pasteur MSD [Member]
Dec. 31, 2012
Sanofi Pasteur MSD [Member]
Dec. 31, 2011
Sanofi Pasteur MSD [Member]
Sep. 29, 2011
Johnson & Johnson Merck Consumer Pharmaceuticals Company [Member]
Dec. 31, 2011
Johnson & Johnson Merck Consumer Pharmaceuticals Company [Member]
Equity Income from Affiliates [Line Items]                          
Percentage of ownership in joint venture               50.00%          
Limited partner interest in AZLP             1.00%            
General partner interest in AZLP             99.00%            
Revenue from AZLP       $ 920,000,000 $ 915,000,000 $ 1,200,000,000              
Agreed-upon payment to be made by AstraZeneca at closing for exercise of option       327,000,000                  
Multiple of average annual profit allocation to be included in option exercise price       10                  
Years prior to option exercise to be included in average annual profit allocation portion of exercise price       3 years                  
Sales of products marketed by the joint venture       4,611,000,000 4,694,000,000 4,659,000,000     1,200,000,000 1,100,000,000 1,100,000,000 62,000,000  
Percentage of interest in equity method investment sold by Merck                         50.00%
Gain on disposition of interest in equity method investment 0 0 136,000,000                   136,000,000
Proceeds from sale of interest in equity method investment 0 0 175,000,000                   175,000,000
Investments in affiliates accounted for using the equity method 1,600,000,000 1,300,000,000                      
Amounts due from equity method affiliates $ 277,000,000 $ 302,000,000